Your session is about to expire
← Back to Search
Iloprost for Lung Cancer Prevention
Study Summary
This trial will compare the effects of inhaled iloprost to a placebo in preventing lung cancer in former smokers.
- Lung Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 2 trial • 152 Patients • NCT00084409Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You must have smoked the equivalent of 20 packs of cigarettes per year or more.
- Group 1: Arm I (iloprost QID)
- Group 2: Arm II (placebo QID)
- Group 3: Arm III (iloprost BID)
- Group 4: Arm IV (placebo BID)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the primary aims of this experimental research?
"This clinical trial, to be assessed over a two-month period, has the goal of measuring incidents of toxicity. Secondary endpoints are whether in vitro responses from cultured airway epithelial progenitor cells can predict iloprost's efficacy; descriptive statistics regarding dysplastic lesion gene expression and endobronchial brushing gene expression focusing on prostacyclin pathways."
Is it possible to enroll in this experiment at present?
"Per the clinicaltrials.gov website, this experiment is not presently seeking participants. It was first publicized on November 5th 2015 and last revised on June 28th 2022. However, 1510 other trials remain open to enrollment at present."
What is the uppermost capacity of participants in this research endeavor?
"Currently, this trial is not accepting new enrollees. It was initially established on November 5th 2015 and last updated June 28th 2022. If you are seeking other research opportunities, 1504 studies for lung carcinoma and 6 trials utilizing Iloprost have open recruitment periods currently."
Is it possible for me to join this scientific experiment?
"In order to meet the criteria of this trial, contenders must possess lung carcinoma and be aged between 18-85. Currently, 34 participants are being sought out for the study."
Has Iloprost received the necessary regulatory clearance from the FDA?
"Iloprost's safety is still largely unknown, with limited clinical data to support efficacy. Our evaluation team at Power thus assigned it a score of 1."
Is this research accommodating participants aged above seventy-five?
"This research programme is looking for volunteers aged 18 and above, but no older than 85."
Share this study with friends
Copy Link
Messenger